uMed for Healthcare Providers
Only 5% of patients participate in clinical trials, together we are bringing research to the 95%.
uMed is supporting the expansion of ACCESS Next-Generation Registries - well-characterized, research-ready cohorts to meet clinical research requirements necessary to develop disease specific therapeutics.
-
For Sites
Generate funding for research - we compensate for study setup and provide funding to supplement research grants.
-
For Staff
Minimize the lengthy process of initiating enrollment in person. We support digital patient outreach, screening and data collection reducing burden on research staff.
-
For Investigators
Make your grant applications more competitive and accurately predict pool of patients available for a specific research project. Our patient engagement services help you demonstrate feasibility to complete projects on time, and on budget.
-
For Patients
Research-driven patients get access to low burden studies from the comfort of their home.
Patient perspectives
“It's been 5 years since my diagnosis but this is my first time taking part in Parkinson's research because of my poor mobility. Being able to take part despite having no internet is a big positive and your nurses make this possible.”
AccessPD participant
Join an ACCESS study specific to your research interests
We put patients and their data first
Patients can opt-out at any time
Reliably safeguarded PHI for tens of thousands of research participant
Patients provide informed consent & HIPAA Authorization to share data
HIPPA compliant
24 hour support line
ISO2701 certified
Frequently asked questions
-
Who is uMed?
uMed is a patient outreach service who work on behalf of healthcare providers and study sponsors, including Cohort Science. They will be providing patient contact and engagement services for this study.
-
Who is Cohort Science?
Cohort Science develops and manages studies and registries and they are the study sponsors for AccessPD, AccessILD and AccessCMD.
-
Will patients be informed of any results?
Each patient enrolled in the study will receive quarterly newsletters updating them on the progress of the registry. We always welcome feedback from our patients taking part and will give opportunities for this regularly.
-
How is patient data used?
We will use information from patients’ medical records that is relevant to the study. We will only use information that we need for the study. This information will be available to researchers in a de-identified form, meaning patients will not be identifiable from this information. Patients will not have any rights to the data or any research developed from the data, including copyright. Patients will not benefit financially from any commercial uses of the data you share as part of the study. Cohort Science owns all rights.
-
Will pharmaceutical companies or other research organizations be involved in ACCESS Registries?
Pharmaceutical and Medical Device companies play a key role in the development of new therapies and will be invited to collaborate with Cohort Science alongside academic and university-based researchers.
-
Are there any risks associated with taking part in an ACCESS Registry?
Whilst every effort will be made to protect patient well-being and dignity, there can still be risks associated with participating in any medical research. Examples of risks include a data breach of information relating to your health information.
Participation in additional research opportunities will always be at patient discretion and will require additional patient consent. It is important to note that the risks will depend entirely on the specific additional research projects that patients participate in, so participation should be carefully considered using all information provided during the invitation. -
Will healthcare institutions be paid for patient involvement in ACCESS Studies?
Participating healthcare institutions and their service providers will be paid administrative costs associated with their involvement in the study.
-
Will patients receive any payment for participation?
No, patients will not receive any payment. If Cohort Science or its affiliates, research partners or collaborators develop any new product, idea, or service using the data in the registry, including those that may have commercial value, patients will have no rights in any such product, idea, or service, and patients will not benefit financially from any of those efforts or product, idea or service.
-
What if the patients no longer want to take part?
Patients can opt out at any time without giving a reason by contacting the study support team using the contact details below. Any data that has already been contributed prior to their discontinuation will remain in the study database.
-
Who should patients contact if they need more information or wish to make a complaint?
Patients can contact our study support team at +1 888 454 5580 or they can email patientsupport@umed.io.
-
What patient participation is expected?
Patients who consent to take part in the study will be sent health and disease related questionnaires which can be completed on a smartphone, computer or with a member of the Cohort Science study support team by phone. These questionnaires will be sent to patients approximately every month. They will ask specific questions regarding their experience of living with the condition (e.g. how their symptoms may have changed or how the condition impacts their daily activities and quality of life, etc).
